# Study to Investigate the Pharmacokinetics, Pharmacodynamics and Assess the Efficacy and Safety to Support Dose Selection of Emapalumab in Pre-empting Graft Failure in Patients at High Risk After HSCT.

> **NCT04731298** · PHASE2 · TERMINATED · sponsor: **Swedish Orphan Biovitrum** · enrollment: 2 (actual)

## Conditions studied

- Graft Failure

## Interventions

- **DRUG:** Emapalumab

## Key facts

- **NCT ID:** NCT04731298
- **Lead sponsor:** Swedish Orphan Biovitrum
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-05-25
- **Primary completion:** 2022-04-21
- **Final completion:** 2022-04-21
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** Sponsor Decision related to Business Priorities, Assessment of Development Options
- **Last updated:** 2023-12-28

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04731298

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04731298, "Study to Investigate the Pharmacokinetics, Pharmacodynamics and Assess the Efficacy and Safety to Support Dose Selection of Emapalumab in Pre-empting Graft Failure in Patients at High Risk After HSCT.". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04731298. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*